FDA to Convene Pharmacy Compounding Advisory Committee in July The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and FDA Moves on Peptides: What Compounding Pharmacies Need to Know FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies